Clinical Trial Update: Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine [Phase 2]

View source ↗

Summary

Phase 2 trial update of lamivudine/dolutegravir in virologically suppressed HIV patients with lamivudine resistance; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• Epivir (Lamivudine)
• Tivicay (dolutegravir)

Snippet

Sponsor: Fundacion SEIMC-GESIDA | Conditions: HIV Infections | Phase 2 | Status: COMPLETED